首页> 外文期刊>Endocrine journal >Evaluation of Diagnostic Tests for ACTH-Dependent Cushing's Syndrome
【24h】

Evaluation of Diagnostic Tests for ACTH-Dependent Cushing's Syndrome

机译:依赖ACTH的库欣综合征的诊断测试评估

获取原文
获取原文并翻译 | 示例
       

摘要

We evaluated the usefulness and accuracy of diagnostic tests for adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome, based on our experience of 88 cases, including 73 cases with Cushing's disease, and 15 cases with ectopic ACTH syndrome (EAS). In our study, 0.5 mg of dexamethasone failed to suppress the morning cortisol secretion in 100% of cases with Cushing's disease and EAS. Plasma ACTH levels were significantly increased by desmopressin (DDAVP) in 86% of cases with Cushing's disease, especially in microadenomas (90%), while these levels were not affected in normal subjects. In EAS, 44% responded to DDAVP. Plasma ACTH levels were increased in response to the human corticotropin-releasing hormone (CRH) test in 100% of microadenomas and 73% of macroadenomas with Cushing's disease, but only in 27% of cases with EAS. A high dose (8 mg) of dexamethasone suppressed the morning cortisol secretion in 89% of microadenomas with Cushing's disease, and in 82% of all cases with Cushing's disease, while it did in only 20% of cases with EAS. Taken together, the 0.5 mg dexamethasone suppression test (DST) and DDAVP test are considerably useful for the screening of ACTH-dependent Cushing's syndrome. The CRH test and 8 mg DST would be effective for the diagnosis of Cushing's diseases, because our study shows a sensitivity of 81% in cases with Cushing's disease when these tests are considered together. These data were submitted to prepare the diagnostic criteria for Cushing's disease, suggested by the working group of the Ministry of Health, Labour, and Welfare of Japan.
机译:我们根据88例经验(包括73例库欣病和15例异位ACTH综合征(EAS))的经验,评估了依赖促肾上腺皮质激素(ACTH)的库欣综合征的诊断测试的有效性和准确性。在我们的研究中,在100%的库欣病和EAS病例中,0.5 mg地塞米松未能抑制早晨皮质醇的分泌。在86%的库欣病患者中,去氨加压素(DDAVP)可显着提高血浆ACTH水平,尤其是在微腺瘤(90%)中,而这些水平在正常受试者中并未受到影响。在EAS中,有44%的人对DDAVP做出了回应。响应人类促肾上腺皮质激素释放激素(CRH)测试,血浆Cath水平在100%的库欣病微腺瘤和73%的大腺瘤中升高,但仅在EAS病例中为27%。高剂量(8毫克)地塞米松抑制了库欣病的89%的微腺瘤和所有库欣病的82%的早晨皮质醇的分泌,而仅在20%的EAS病例中抑制了。总而言之,0.5 mg地塞米松抑制试验(DST)和DDAVP试验对于筛查ACTH依赖的库欣氏综合症非常有用。 CRH测试和8 mg DST对Cushing病的诊断是有效的,因为我们的研究表明,将Cushing病与这些测试一起考虑时灵敏度为81%。这些数据是日本厚生劳动省工作组提出的,用于准备库欣氏病的诊断标准。

著录项

  • 来源
    《Endocrine journal》 |2009年第3期|469-476|共8页
  • 作者单位

    Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan;

    Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan;

    Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan;

    Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    ACTH; cortisol; cushing's disease; pituitary; adrenal gland;

    机译:ACTH;皮质醇库欣病垂体;肾上腺;
  • 入库时间 2022-08-18 01:33:46

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号